Guest guest Posted November 18, 2010 Report Share Posted November 18, 2010 I guess I must be the only one on this group who is not impressed by this Dendreon - Provenge " adventure " . Gaining four months survival at the end of life with Provenge, but still stuck on castration drugs, is not my idea of scientific or medical greatness. You could possibly get as long, maybe more by going on testosterone patches - and have a much happier time of it too ! Now, if anyone is excited about Provenge being a money-spinner that is a different matter, and I can see why so many are putting / have put their names to the " Let's all get Provenge OK'd by the FDA " . There are other investment goodies coming up, like Alpharadin for instance. But if / when you do your homework you'll see there is no advantage over Metastron. Provenge, like Alpharadin and like Dutasteride a while ago, will generate a lot of froth and the kind of circuitous investment activity that got the whole investment world into trouble a couple of years ago. The reason: simply because there is no real inherent profit or true social value in this stuff. Compared to a real cure for prostate cancer, or a significant extension of life - years not a handful of months, these market goodies are for the punters, not the patients. This link gives an example of what I am talking about.http://www.nytimes.com/2010/11/18/health/18prostate.html?_r=2 & hpw There is also a commentary on the Provenge - FDA issue showing just how close Dendreon have cut it. If I were to put my money on anything to do with Dendreon, I'd say they were chasing overheads and losses from 15 years of developing this essentially failed drug. 4 months ? Give us a break ! Sam. Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.